High-dose chemotherapy and autologous bone marrow rescue followed by interstitial and external-beam radiotherapy in newly diagnosed pediatric malignant gliomas

R. L. Heideman, E. C. Douglass, R. A. Krance, J. Fontanesi, J. A. Langston, R. A. Sanford, E. H. Kovnar, J. Ochs, J. Kuttesch, J. J. Jenkins, D. L. Fairclough, L. E. Kun

Research output: Contribution to journalArticle

64 Citations (Scopus)

Abstract

Purpose: Evaluation of high-dose chemotherapy with autologous bone marrow rescue (ABMR) in pediatric malignant gliomas. Patients and Methods: Newly diagnosed (n = 11) and recurrent (n = 2) malignant glioma patients received high-dose chemotherapy within 4 weeks of surgery; three had near total and 10 had subtotal resection/biopsy. High-dose thiotepa (300 mg/m2) and cyclophosphamide (2 g/m2) daily for 3 days were followed by ABMR; response was evaluated at day 30. At day 60, patients with at least stable disease received hyperfractionated (n = 9) or conventional external-beam radiotherapy (n = 2) preceded by local radioactive iodine 125 implantation (n = 2) or radiosurgery (n = 1). Results: Grade III and IV toxicities after ABMR consisted of mucositis (n = 12), cardiomyopathy (n = 1), acute abdomen (n = 1), pneumonitis (n = 2), and infection (n = 2). One complete and three partial responses were observed; the objective response rate was 31% (95% confidence interval, 9% to 61%). Seven had stable disease, one had disease progression, and one died of toxicity before response evaluation. The median overall and progression-free survival durations after combined modality therapy were 14 months (range, 4 to 30 +) and 9 months (range, 0 to 30 +), respectively. One patient remains progression-free at 30 + months. Radionecrosis and white matter changes occurred in three patients: one after hyperfractionated irradiation, and two after 125I implants. Conclusion: For patients with bulky residual disease after surgery, survival with this aggressive chemotherapy and radiation regimen is no better than that reported for conventional treatment regimens.

Original languageEnglish (US)
Pages (from-to)1458-1465
Number of pages8
JournalJournal of Clinical Oncology
Volume11
Issue number8
DOIs
StatePublished - Jan 1 1993

Fingerprint

Glioma
Radiotherapy
Bone Marrow
Pediatrics
Drug Therapy
Thiotepa
Combined Modality Therapy
Mucositis
Acute Abdomen
Radiosurgery
Cardiomyopathies
Iodine
Cyclophosphamide
Disease-Free Survival
Disease Progression
Pneumonia
Confidence Intervals
Radiation
Biopsy
Survival

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

High-dose chemotherapy and autologous bone marrow rescue followed by interstitial and external-beam radiotherapy in newly diagnosed pediatric malignant gliomas. / Heideman, R. L.; Douglass, E. C.; Krance, R. A.; Fontanesi, J.; Langston, J. A.; Sanford, R. A.; Kovnar, E. H.; Ochs, J.; Kuttesch, J.; Jenkins, J. J.; Fairclough, D. L.; Kun, L. E.

In: Journal of Clinical Oncology, Vol. 11, No. 8, 01.01.1993, p. 1458-1465.

Research output: Contribution to journalArticle

Heideman, RL, Douglass, EC, Krance, RA, Fontanesi, J, Langston, JA, Sanford, RA, Kovnar, EH, Ochs, J, Kuttesch, J, Jenkins, JJ, Fairclough, DL & Kun, LE 1993, 'High-dose chemotherapy and autologous bone marrow rescue followed by interstitial and external-beam radiotherapy in newly diagnosed pediatric malignant gliomas', Journal of Clinical Oncology, vol. 11, no. 8, pp. 1458-1465. https://doi.org/10.1200/JCO.1993.11.8.1458
Heideman, R. L. ; Douglass, E. C. ; Krance, R. A. ; Fontanesi, J. ; Langston, J. A. ; Sanford, R. A. ; Kovnar, E. H. ; Ochs, J. ; Kuttesch, J. ; Jenkins, J. J. ; Fairclough, D. L. ; Kun, L. E. / High-dose chemotherapy and autologous bone marrow rescue followed by interstitial and external-beam radiotherapy in newly diagnosed pediatric malignant gliomas. In: Journal of Clinical Oncology. 1993 ; Vol. 11, No. 8. pp. 1458-1465.
@article{5ac3457d22284cc385aa1df9b35ea494,
title = "High-dose chemotherapy and autologous bone marrow rescue followed by interstitial and external-beam radiotherapy in newly diagnosed pediatric malignant gliomas",
abstract = "Purpose: Evaluation of high-dose chemotherapy with autologous bone marrow rescue (ABMR) in pediatric malignant gliomas. Patients and Methods: Newly diagnosed (n = 11) and recurrent (n = 2) malignant glioma patients received high-dose chemotherapy within 4 weeks of surgery; three had near total and 10 had subtotal resection/biopsy. High-dose thiotepa (300 mg/m2) and cyclophosphamide (2 g/m2) daily for 3 days were followed by ABMR; response was evaluated at day 30. At day 60, patients with at least stable disease received hyperfractionated (n = 9) or conventional external-beam radiotherapy (n = 2) preceded by local radioactive iodine 125 implantation (n = 2) or radiosurgery (n = 1). Results: Grade III and IV toxicities after ABMR consisted of mucositis (n = 12), cardiomyopathy (n = 1), acute abdomen (n = 1), pneumonitis (n = 2), and infection (n = 2). One complete and three partial responses were observed; the objective response rate was 31{\%} (95{\%} confidence interval, 9{\%} to 61{\%}). Seven had stable disease, one had disease progression, and one died of toxicity before response evaluation. The median overall and progression-free survival durations after combined modality therapy were 14 months (range, 4 to 30 +) and 9 months (range, 0 to 30 +), respectively. One patient remains progression-free at 30 + months. Radionecrosis and white matter changes occurred in three patients: one after hyperfractionated irradiation, and two after 125I implants. Conclusion: For patients with bulky residual disease after surgery, survival with this aggressive chemotherapy and radiation regimen is no better than that reported for conventional treatment regimens.",
author = "Heideman, {R. L.} and Douglass, {E. C.} and Krance, {R. A.} and J. Fontanesi and Langston, {J. A.} and Sanford, {R. A.} and Kovnar, {E. H.} and J. Ochs and J. Kuttesch and Jenkins, {J. J.} and Fairclough, {D. L.} and Kun, {L. E.}",
year = "1993",
month = "1",
day = "1",
doi = "10.1200/JCO.1993.11.8.1458",
language = "English (US)",
volume = "11",
pages = "1458--1465",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "8",

}

TY - JOUR

T1 - High-dose chemotherapy and autologous bone marrow rescue followed by interstitial and external-beam radiotherapy in newly diagnosed pediatric malignant gliomas

AU - Heideman, R. L.

AU - Douglass, E. C.

AU - Krance, R. A.

AU - Fontanesi, J.

AU - Langston, J. A.

AU - Sanford, R. A.

AU - Kovnar, E. H.

AU - Ochs, J.

AU - Kuttesch, J.

AU - Jenkins, J. J.

AU - Fairclough, D. L.

AU - Kun, L. E.

PY - 1993/1/1

Y1 - 1993/1/1

N2 - Purpose: Evaluation of high-dose chemotherapy with autologous bone marrow rescue (ABMR) in pediatric malignant gliomas. Patients and Methods: Newly diagnosed (n = 11) and recurrent (n = 2) malignant glioma patients received high-dose chemotherapy within 4 weeks of surgery; three had near total and 10 had subtotal resection/biopsy. High-dose thiotepa (300 mg/m2) and cyclophosphamide (2 g/m2) daily for 3 days were followed by ABMR; response was evaluated at day 30. At day 60, patients with at least stable disease received hyperfractionated (n = 9) or conventional external-beam radiotherapy (n = 2) preceded by local radioactive iodine 125 implantation (n = 2) or radiosurgery (n = 1). Results: Grade III and IV toxicities after ABMR consisted of mucositis (n = 12), cardiomyopathy (n = 1), acute abdomen (n = 1), pneumonitis (n = 2), and infection (n = 2). One complete and three partial responses were observed; the objective response rate was 31% (95% confidence interval, 9% to 61%). Seven had stable disease, one had disease progression, and one died of toxicity before response evaluation. The median overall and progression-free survival durations after combined modality therapy were 14 months (range, 4 to 30 +) and 9 months (range, 0 to 30 +), respectively. One patient remains progression-free at 30 + months. Radionecrosis and white matter changes occurred in three patients: one after hyperfractionated irradiation, and two after 125I implants. Conclusion: For patients with bulky residual disease after surgery, survival with this aggressive chemotherapy and radiation regimen is no better than that reported for conventional treatment regimens.

AB - Purpose: Evaluation of high-dose chemotherapy with autologous bone marrow rescue (ABMR) in pediatric malignant gliomas. Patients and Methods: Newly diagnosed (n = 11) and recurrent (n = 2) malignant glioma patients received high-dose chemotherapy within 4 weeks of surgery; three had near total and 10 had subtotal resection/biopsy. High-dose thiotepa (300 mg/m2) and cyclophosphamide (2 g/m2) daily for 3 days were followed by ABMR; response was evaluated at day 30. At day 60, patients with at least stable disease received hyperfractionated (n = 9) or conventional external-beam radiotherapy (n = 2) preceded by local radioactive iodine 125 implantation (n = 2) or radiosurgery (n = 1). Results: Grade III and IV toxicities after ABMR consisted of mucositis (n = 12), cardiomyopathy (n = 1), acute abdomen (n = 1), pneumonitis (n = 2), and infection (n = 2). One complete and three partial responses were observed; the objective response rate was 31% (95% confidence interval, 9% to 61%). Seven had stable disease, one had disease progression, and one died of toxicity before response evaluation. The median overall and progression-free survival durations after combined modality therapy were 14 months (range, 4 to 30 +) and 9 months (range, 0 to 30 +), respectively. One patient remains progression-free at 30 + months. Radionecrosis and white matter changes occurred in three patients: one after hyperfractionated irradiation, and two after 125I implants. Conclusion: For patients with bulky residual disease after surgery, survival with this aggressive chemotherapy and radiation regimen is no better than that reported for conventional treatment regimens.

UR - http://www.scopus.com/inward/record.url?scp=0027183528&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027183528&partnerID=8YFLogxK

U2 - 10.1200/JCO.1993.11.8.1458

DO - 10.1200/JCO.1993.11.8.1458

M3 - Article

C2 - 8336185

AN - SCOPUS:0027183528

VL - 11

SP - 1458

EP - 1465

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 8

ER -